Black Diamond Therapeutics, Inc. (BDTX) Stock Price & Analysis

Black Diamond Therapeutics, Inc. (BDTX) rose 2.70% to USD 1.9 as of June 10, 2026 at 00:47 UTC, according to Nexqual real-time market data.

BDTX last closed at USD 1.85; the session ranged USD 1.85–1.94 on volume of 1,711,143 shares. Market capitalization is $108.87M, with a 52-week range of USD 1.85–4.94 (NMS). Source: Nexqual, June 10, 2026 at 00:47 UTC.

Key Statistics (as of June 10, 2026 at 00:47 UTC)

Technical Analysis (BDTX)

Nexqual's technical model rates BDTX "SELL" based on 1 bullish and 5 bearish signals across 124 daily candles, as of June 10, 2026 at 00:47 UTC.

Analyst Ratings (BDTX)

Wall Street analysts rate BDTX "Strong Buy" based on 7 analysts, with a mean price target of USD 9.86 (range USD 7–14), per Nexqual as of June 10, 2026 at 00:47 UTC.

Earnings (BDTX)

Recent Earnings History

Source: Nexqual, June 10, 2026 at 00:47 UTC.

Financials & Fundamentals (BDTX)

Source: Nexqual, June 10, 2026 at 00:47 UTC.

Financial Health Score (BDTX)

Nexqual rates Black Diamond Therapeutics, Inc.'s overall financial health "Weak" across five dimensions, as of June 10, 2026 at 00:47 UTC.

Ownership (BDTX)

Source: Nexqual, June 10, 2026 at 00:47 UTC.

Leadership (BDTX)

Black Diamond Therapeutics, Inc. is led by Mark A. Velleca (age 61), CEO, President & Chairman, per Nexqual as of June 10, 2026 at 00:47 UTC.

Major Backers & Investors (BDTX)

Notable institutional backers of Black Diamond Therapeutics, Inc. include T. Rowe Price, NEA Management Company, LLC, -Price (T.Rowe) U.S. Small-Cap Value Equity Trust, according to Nexqual as of June 10, 2026 at 00:47 UTC.

Active Investors

Index Funds (Passive)

Source: Nexqual, June 10, 2026 at 00:47 UTC.

From Black Diamond Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-03-16)

Key Strengths & Strategy (as disclosed to the SEC)

• Our MasterKey therapies were discovered using our proprietary MAP drug discovery engine which was built on three central pillars: identification of oncogenic mutations, confirmation of oncogenicity of mutations based upon cell and tumor models, and pharmacologic inhibition of the relevant mutations while sparing wild-type.
• Intellectual property We seek to protect the intellectual property and proprietary technology that we consider important to our business, including by pursuing patent applications that cover our product candidates and methods of using the same, as well as any other relevant inventions and improvements that are considered commercially important to the development of our business.
• We also rely on trade secrets, know-how and continuing technological innovation to develop and maintain our proprietary and intellectual property position.
• As with other biotechnology and pharmaceutical companies, our ability to maintain and solidify our proprietary and intellectual property position for our product candidates and technologies will depend on our success in obtaining effective patent claims and enforcing those claims if granted.

Partnerships

• Based upon real-world evidence gathered in collaboration with Guardant Health, these patients have significant unmet medical needs.
• In consideration for the license granted to Servier, we received an upfront payment of $70.0 million in March 2025 and will be eligible to receive up to $710.0 million in development and commercial sales milestone payments, along with tiered royalties based on global net sales.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 00:47 UTC. This page is informational and not investment advice.